Format

Send to

Choose Destination
J Cardiothorac Surg. 2018 Aug 24;13(1):91. doi: 10.1186/s13019-018-0773-y.

Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial.

Author information

1
Department of Interventional Radiology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. j.palussiere@bordeaux.unicancer.fr.
2
Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.
3
Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.
4
Department of Interventional Imaging, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, Paris, France.
5
Department of Imaging, CHU Timone, 264 Rue Saint-Pierre, 13385, Marseille, France.
6
Department of Imaging, CHU Pau, 4 Boulevard Hauterive, 64000, Pau, France.
7
Department of Imaging, CHU Haut Lévêque, Avenue Magellan, 33600, Pessac, France.
8
Department of Imaging, CHU Rennes, 2 rue Henri Le Guilloux, 35033, Rennes, France.

Abstract

BACKGROUND:

A prospective multicenter phase II trial to evaluate the survival outcomes of percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung cancer (NSCLC), ineligible for surgery.

METHODS:

Patients with a biopsy-proven stage IA NSCLC, staging established by a positron emission tomography-computed tomography (PET-CT), were eligible. The primary objective was to evaluate the local control of RFA at 1-year. Secondary objectives were 1- and 3-year overall survival (OS), 3-year local control, lung function (prior to and 3 months after RFA) and quality of life (prior to and 1 month after RFA).

RESULTS:

Of the 42 patients (mean age 71.7 y) that were enrolled at six French cancer centers, 32 were eligible and assessable. Twenty-seven patients did not recur at 1 year corresponding to a local control rate of 84.38% (95% CI, [67.21-95.72]). The local control rate at 3 years was 81.25% (95% CI, [54.35-95.95]). The OS rate was 91.67% (95% CI, [77.53-98.25]) at 1 year and 58.33% (95% CI, [40.76-74.49]) at 3 years. The forced expiratory volume was stable in most patients apart from two, in whom we observed a 10% decrease. There was no significant change in the global health status or in the quality of life following RFA.

CONCLUSION:

RFA is an efficient treatment for medically inoperable stage IA NSCLC patients. RFA is well tolerated, does not adversely affect pulmonary function and the 3-year OS rate is comparable to that of stereotactic body radiotherapy, in similar patients.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier NCT01841060 registered in November 2008.

KEYWORDS:

Ablation; Non-small cell lung cancer; Radiofrequency ablation; Stereotactic body radiotherapy

PMID:
30143031
PMCID:
PMC6109264
DOI:
10.1186/s13019-018-0773-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center